ER
ALDR

Enlightenment Research’s Alder Biopharmaceuticals ALDR Stock Holding History

Enlightenment Research’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$2K – 797
2018
Q4 		$2K Buy
+200
New +$2.56K ﹤0.01% 771

Other funds holding ALDR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Enlightenment Research's ALDR Position: Q1 2019 in Review

Enlightenment Research sold out of Alder Biopharmaceuticals (ALDR) in Q1 2019, closing a stake of 200 shares — an estimated $2K sold.

Enlightenment Research first reported a position in ALDR in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 123 funds tracked by Wall St. Rank hold ALDR as of Q1 2019.

  • Enlightenment Research reported no remaining Alder Biopharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 200 Alder Biopharmaceuticals shares in Q1 2019, an estimated $2K.
  • Enlightenment Research first reported a position in Alder Biopharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Alder Biopharmaceuticals position peaked at $2K in Q4 2018.
  • 123 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.